Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing

Psychedelic therapy is emerging as a clinically validated approach for treating resistant mental health conditions, moving beyond the traditional symptom management model where pharmaceutical drugs are merely taken daily. Recent progress, such as Compass Pathways' phase 3 trials for COMP 360, highlights a significant market shift. Experts such as Dr. Will Van Derveer and Keith Kurlander stress that this approach involves a structured, interventional process combining medicine with therapy, which contrasts with traditional psychopharmacology. Treatment often requires only a limited number of sessions, potentially leading to durable benefits for patients who have not responded to standard options, addressing a large, underserved global demographic. Investment opportunities lie within the biopharma sector developing these compounds, though long term success and scaling remain challenging. Market expansion will depend heavily on regulatory developments at the federal level and advancements in training for specialized providers, as the therapy requires careful, hands-on administration to ensure safety and effectiveness.